2 results for “efavirenz”

Set a search alert

Research ArticleOpen accessIn the keywordsThe Lipid-Lowering Efficacy of Switching Within Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected PatientsA.M. Bain, K.D. Payne, A.P. Rahman et al.The objective of present research is to evaluate the lipid lowering efficacy and safety of switching within non-nucleoside reverse transcriptase inhibitors (NNRTI) in HIV-infected patients. This is a multicenter, retrospective study utilizing a comprehensive electronic patient registry to identify all adult HIV-infected patients seen from October 1, 1998 through October 1, 2006, who substituted efavirenz for nevirapine (EFV→NVP) or vice-versa … …American Journal of Infectious Diseases, Vol. 4, Issue 2 · 30 Jun 2008 · 6,743 accessesView PDF Cite

Research ArticleOpen accessIn the abstractEfficacy of Pravastatin in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and Protease Inhibitor (PI)-based HAART in HIV-Infected PatientsSusan A. Eaton, Anita P. Rahman, Sean T. Nguyen et al.Pravastatin has generally been considered a safe and effective option for HIV-infected patients on highly active antiretroviral therapy (HAART). However, pravastatin concentrations are known to significantly decrease with concomitant efavirenz (EFV) use. Currently there are no studies determining if these reductions in pravastatin possibly translate into an attenuation of its lipid lowering efficacy when used in HIV-infected patients on non-nucleoside … …American Journal of Infectious Diseases, Vol. 4, Issue 2 · 30 Jun 2008 · 6,959 accessesView PDF Cite